×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PIRS – pieris pharmaceuticals, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PIRS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
03:06 am
pirs
Nouscom Appoints Seasoned Executive Eckhard Niemeier as Chief Business Officer [Yahoo! Finance]
Low
Report
Nouscom Appoints Seasoned Executive Eckhard Niemeier as Chief Business Officer [Yahoo! Finance]
11/20
05:29 pm
pirs
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
Low
Report
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
11/20
12:04 am
pirs
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/11
11:15 pm
pirs
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/11
11:15 pm
pirs
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/7
08:30 am
pirs
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
Medium
Report
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
10/17
07:30 am
pirs
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Low
Report
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
10/3
07:49 am
pirs
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations [Yahoo! Finance]
Low
Report
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/20
05:33 pm
pirs
Form SCHEDULE 13D PALVELLA THERAPEUTICS, Filed by: Kaupinen Wes
Neutral
Report
Form SCHEDULE 13D PALVELLA THERAPEUTICS, Filed by: Kaupinen Wes
12/20
05:00 pm
pirs
Form SCHEDULE 13G PALVELLA THERAPEUTICS, Filed by: Samsara BioCapital, L.P.
Neutral
Report
Form SCHEDULE 13G PALVELLA THERAPEUTICS, Filed by: Samsara BioCapital, L.P.
12/20
04:57 pm
pirs
Form SCHEDULE 13G PALVELLA THERAPEUTICS, Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
Neutral
Report
Form SCHEDULE 13G PALVELLA THERAPEUTICS, Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
12/16
07:45 pm
pirs
Form 3 PALVELLA THERAPEUTICS, For: Dec 13 Filed by: Wessel Tadd S.
Neutral
Report
Form 3 PALVELLA THERAPEUTICS, For: Dec 13 Filed by: Wessel Tadd S.
12/16
07:45 pm
pirs
Form 3 PALVELLA THERAPEUTICS, For: Dec 13 Filed by: Korenberg Matthew E
Neutral
Report
Form 3 PALVELLA THERAPEUTICS, For: Dec 13 Filed by: Korenberg Matthew E
12/16
07:44 pm
pirs
Form 3 PALVELLA THERAPEUTICS, For: Dec 13 Filed by: Kaupinen Wes
Neutral
Report
Form 3 PALVELLA THERAPEUTICS, For: Dec 13 Filed by: Kaupinen Wes
12/16
07:43 pm
pirs
Form 3 PALVELLA THERAPEUTICS, For: Dec 13 Filed by: Martini Jeffrey S
Neutral
Report
Form 3 PALVELLA THERAPEUTICS, For: Dec 13 Filed by: Martini Jeffrey S
12/16
07:43 pm
pirs
Form 3 PALVELLA THERAPEUTICS, For: Dec 13 Filed by: Goin Kathleen
Neutral
Report
Form 3 PALVELLA THERAPEUTICS, For: Dec 13 Filed by: Goin Kathleen
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating.
34.2%
7/30 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. 13.7%
7/26 Form 4 PIERIS PHARMACEUTICALS, For: Jul 25 Filed by: Richman Michael 12.2%
11/5 Pieris Pharmaceuticals to Present Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 11.5%
5/13 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 9.9%
3/18 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 9.7%
11/4 Pieris Pharmaceuticals to Host Third Quarter 2019 Investor Call and Corporate Update on November 11, 2019 9.0%
3/23 Pieris Pharmaceuticals Provides Update on Servier Collaboration 8.1%
11/13 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 7.9%
5/10 Form 10-Q PIERIS PHARMACEUTICALS, For: Mar 31 7.3%
7/30 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. 13.7%
7/26 Form 4 PIERIS PHARMACEUTICALS, For: Jul 25 Filed by: Richman Michael 12.2%
11/5 Pieris Pharmaceuticals to Present Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 11.5%
5/13 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 9.9%
3/18 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 9.7%
11/4 Pieris Pharmaceuticals to Host Third Quarter 2019 Investor Call and Corporate Update on November 11, 2019 9.0%
3/23 Pieris Pharmaceuticals Provides Update on Servier Collaboration 8.1%
11/13 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 7.9%
5/10 Form 10-Q PIERIS PHARMACEUTICALS, For: Mar 31 7.3%
TOP News Decliners
3/12
Pieris Pharmaceuticals Reports Full-Year 2019 Financial Results And Provides Corporate Update
-26.8%
9/27 Form 8-K PIERIS PHARMACEUTICALS, For: Sep 27 -18.5%
9/26 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -17.1%
11/12 Form 424B5 PIERIS PHARMACEUTICALS, -15.5%
3/18 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -12.9%
3/27 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock. -11.1%
12/4 Form S-3 PIERIS PHARMACEUTICALS, -9.7%
3/13 Form 10-K PIERIS PHARMACEUTICALS, For: Dec 31 -8.8%
7/31 Form 8-K PIERIS PHARMACEUTICALS, For: Jul 31 -8.7%
9/23 Form 8-K PIERIS PHARMACEUTICALS, For: Sep 20 -8.5%
9/27 Form 8-K PIERIS PHARMACEUTICALS, For: Sep 27 -18.5%
9/26 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -17.1%
11/12 Form 424B5 PIERIS PHARMACEUTICALS, -15.5%
3/18 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -12.9%
3/27 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock. -11.1%
12/4 Form S-3 PIERIS PHARMACEUTICALS, -9.7%
3/13 Form 10-K PIERIS PHARMACEUTICALS, For: Dec 31 -8.8%
7/31 Form 8-K PIERIS PHARMACEUTICALS, For: Jul 31 -8.7%
9/23 Form 8-K PIERIS PHARMACEUTICALS, For: Sep 20 -8.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: